Centene Corporation (CNC) Stock Price & How to Invest

Centene Corporation is a St. Louis-based managed-care organization that administers government-sponsored and subsidized health insurance. It is the largest Medicaid managed-care company in the country (roughly 12.5 million members across about 30 states), the top carrier on the Affordable Care Act Marketplace (around 5.5 million members), and a meaningful Medicare player with about 1.0 million Medicare Advantage members plus roughly 8.1 million prescription-drug-plan members. The company reported total revenue of about $194.8 billion in 2025 and about $180 billion over the trailing twelve months to June 2026, and the vast majority of that flows from Medicaid, Marketplace (commercial), and Medicare premiums, making Centene highly exposed to federal and state healthcare policy, reimbursement rates, and medical cost trends.

The investment picture is defined by a sharp reset and a recovery. In mid-2025 Centene withdrew its full-year guidance after an independent actuarial review found its ACA Marketplace risk-adjustment and morbidity assumptions were too optimistic, and the stock fell about 40% in a single session. The company booked a net loss of about $6.7 billion for 2025, driven by a roughly $6.6 billion loss in the third quarter. Since then results have run well ahead of a cautious Street: Q1 2026 adjusted EPS of about $3.37 against an estimate near $2.13, then Q2 2026 adjusted EPS of about $2.51 against roughly $1.08, on revenue of about $53.6 billion. Management raised its 2026 EPS guidance again after Q2, and analysts now expect about $4.88 of adjusted EPS on roughly $196 billion of revenue for the year.

The stock closed at about $69.55 on October 16, 2026, near the top of a 52-week range of roughly $31.63 to $71.21, for a market cap near $34 billion. In October the company announced a nationwide gold card program that eases prior authorization for qualifying providers starting in November, and the redemption of its remaining 4.25% notes due 2027. Q3 2026 results are scheduled for October 27, with consensus calling for only about $0.10 of EPS, a reminder that the second half of the year is seasonally weaker for this business.

Centene withdrew its 2025 guidance and its stock fell roughly 40% in a single day in July 2025 after actuaries flagged that its ACA Marketplace assumptions were too aggressive, so guidance credibility and forecasting accuracy remain live concerns even after two strong 2026 quarters. The stock has nearly doubled over the past year, so expectations are now higher than they were. Consensus for Q3 2026 is only about $0.10 of EPS and for Q4 a loss of about $1.09, so the second half carries little margin for cost surprises. Medicaid is the single largest source of revenue, and federal legislation enacted in 2025 is projected to cut a large amount of Medicaid funding over the coming years, which could reduce enrollment and pressure rates. Medical cost trends in behavioral health, home health, and high-cost drugs have run hotter than expected, and results are sensitive to state rate negotiations, redeterminations, ACA subsidy policy and the outcome of the November 2026 midterm elections. On a trailing basis the company still shows a net loss of about $5.1 billion because of the 2025 charges.

18 analysts publish price targets on CNC, averaging $71.78 against a $69.16 price as of October 2026, or +3.8%. The published targets run from $56.00 to $85.00, a moderate spread, and the ratings split 8 buy, 12 hold, 1 sell. Over the last six months there have been 10 raises and 0 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full CNC forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

We give no verdict on Centene Corporation. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. Medicaid scale and margin recovery. Centene is the largest Medicaid managed-care organization in the US, with about 12.5 million members across roughly 30 states. The most optimistic published target, $85.00, assumes this works close to its best case.

The case against. Centene withdrew its 2025 guidance and its stock fell roughly 40% in a single day in July 2025 after actuaries flagged that its ACA Marketplace assumptions were too aggressive, so guidance credibility and forecasting accuracy remain live concerns even after two strong 2026 quarters. The most pessimistic target, $56.00, is roughly what CNC is worth if this bites instead.

Read the full bull and bear case on CNC, including what would have to change to break either one. Walnut is not an investment adviser.

Yes. Centene Corporation (CNC) has had one share split in the last 10 years:

• 2:1 on February 7, 2019, so every share held became 2 shares.

A split changes the share count and the price per share and leaves the value of a holding unchanged. Someone holding $1,000 of CNC the day before the 2:1 split held $1,000 the day after, in more shares at a proportionally lower price. Historical prices from before the date are normally shown split-adjusted, which is why a long-run chart shows no cliff.

Splits matter mainly because they make older price figures confusing to compare by hand, and because a board choosing to split is usually signalling that the price has run up far enough to feel awkward for smaller buyers. Neither is a reason to buy or sell.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Centene Corporation's investor relations page or your broker.

• Revenue (TTM): ~$180B
• Revenue growth (Q2 2026, yoy): ~4.6%
• Q2 2026 adjusted EPS: ~$2.51 (est. ~$1.08)
• Net income (TTM): ~-$5.1B (2025 charges)
• Operating margin (TTM): ~3.8%
• Forward P/E: ~13x
• 2026 EPS consensus: ~$4.88
• Market cap: ~$34B

Centene trades near 13 times forward earnings and about 0.19 times sales, still a discount to higher-margin managed-care peers even after a 95% one-year gain. The trailing P/E is not meaningful because of the 2025 loss, so the valuation rests on whether 2026 EPS near $4.88 and 2027 estimates near $5.35 hold. Health insurance is a thin-margin business, so small changes in the health-benefits ratio move earnings sharply.

If you want CNC exposure as part of a larger bundle rather than directly, these ETFs hold it meaningfully. Weights are approximate and refresh quarterly.

Other names that sit close to CNC: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. Worth a look if you are thinking about diversification within a thesis rather than concentration on one ticker.

There are three common ways to get CNC exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it (VFLO), which spreads the position across many companies. Or build it into a focused thematic portfolio, so CNC sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where CNC fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

CNC is a scale player in Medicaid and Marketplace insurance that has spent 2026 rebuilding margins and credibility after pulling its 2025 guidance. Two clear beats have nearly doubled the stock off its lows; the Q3 report on October 27, 2026, cost trends and Medicaid policy decide what comes next.

Whether CNC is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is CNC a buy or a sell?, and where the stock could go from here in the CNC stock forecast.

For income investors, whether CNC pays a dividend and how the payout looks is covered in does CNC pay a dividend? And to weigh CNC against a peer, read the full side-by-side comparisons: CNC vs UNH and CNC vs ELV.